Neisseria meningitidis B vaccines

References

• Al-Tawfiq JA, Clark TA, Memish ZA. Meningococcal disease: the organism, clinical presentation, and worldwide epidemiology. J. Travel. Med.17(Suppl. 3–8), (2010).
   PubMed Web of Science ®Google Scholar
• Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin. Infect. Dis.50(Suppl. 2), S37–S44 (2010).
   PubMed Web of Science ®Google Scholar
• Hill DJ, Griffiths NJ, Borodina E, Virji M. Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease. Clin. Sci. (Lond.)118(9), 547–564 (2010).
   PubMed Web of Science ®Google Scholar
• Branham SE. Serological relationships among meningococci. Bact. Rev.17, 175–188 (1953).
   PubMedGoogle Scholar
• Vedros NA. Development of meningococcal serogroups. In: Evolution of Meningococcal Disease. Vedros NA (Ed.). CRC Press, Roca Raton, FL, USA, 33–37 (1987).
   Google Scholar
• Granoff DM, Harrison LH, Borrow R. Meningococcal vaccines. In: Vaccines, 5th ed. Plokin SA, Orestein WA (Eds). WB Saunders Co, Philadelphia, PA, USA (2008).
   Google Scholar
• Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet369, 2196–2210 (2007).
   PubMed Web of Science ®Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine27(Suppl. 2), B51–B63 (2009).
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A. Meningococcal vaccine in travelers. Curr. Opin. Infect. Dis.20(5), 454–460 (2007).
   PubMed Web of Science ®Google Scholar
• Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet369, 2196–2210 (2007).
   PubMed Web of Science ®Google Scholar
• van Deuren M, Brandtzaeg P, van der Meer JW. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin. Microbiol. Rev.13, 144–166 (2000).
   PubMed Web of Science ®Google Scholar
• Rosenstein NE, Perkins BA, Stephens DS et al. The changing epidemiology of meningococcal disease in the United States, 1992–1996. J. Infect. Dis.180(6), 1894–1901 (1999).
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Harrison LH et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin. Infect. Dis.50(2), 184–191 (2010).
   PubMed Web of Science ®Google Scholar
• Trotter C, Findlow J, Balmer P et al. Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England. Clin. Vaccine Immunol.14(7), 863–868 (2007).
   PubMedGoogle Scholar
• Meningococcal Reference Unit, Gray SJ, Trotter CL et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J. Med. Microbiol.55(7), 887–896 (2006).
   PubMed Web of Science ®Google Scholar
• Häyrinen J, Jennings H, Raff HV et al. Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides. J. Infect. Dis.171(6), 1481–1490 (1995).
   PubMed Web of Science ®Google Scholar
• Novak N, Bieber T. Dendritic cells as regulators of immunity and tolerance. J. Allergy Clin. Immunol.121(Suppl. 2), S370–S374 (2008).
   PubMed Web of Science ®Google Scholar
• Kolb-Maurer A, Unkmeir A, Kammerer U. Interaction of Neisseria meningitidis with human dendritic cells. Infect. Immun.69, 6912–6922 (2001).
   PubMed Web of Science ®Google Scholar
• Jones HE, Uronen-Hanson H, Callard RE, Klein N, Dixon GL. The differential response of human dendritic cells to live and killed Neisseria Meningitidis. Cell. Microbiol.9, 2856–2869 (2007).
   PubMed Web of Science ®Google Scholar
• Hammerschmidt S, Birkholz C, Zahringer U et al. Contribution of genes from the capsule gene complex (cps) to lipooligosaccharide biosynthesis and serum resistance in Neisseria meningitidis. Mol. Microbiol.11, 885–896 (1994).
   PubMed Web of Science ®Google Scholar
• Vogel U, Weinberger A, Frank R et al. Complement factor C3 deposition and serum resistance in isogenic capsule and lipooligosaccharide sialic acid mutants of serogroup B Neisseria meningitidis. Infect. Immun.65, 4022–4029 (1997).
   PubMed Web of Science ®Google Scholar
• Geoffroy MC, Floquet S, Metais A, Nassif X, Pelicic V. Large-scale analysis of the meningococcus genome by gene disruption: resistance to complement-mediated lysis. Genome. Res.13, 391–398 (2003).
   PubMed Web of Science ®Google Scholar
• Lewis LA, Ngampasutadol J, Wallace R, Reid JE, Vogel U, Ram S. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog.6(7), e1001027 (2010).
   PubMed Web of Science ®Google Scholar
• Schneider MC, Exely RM, Ram S, Sim RB, Tang CM. Interactions between Neisseria meningitidis and the complement system. Trends Microbiol.15, 233–240 (2007).
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med.129, 1307–1326 (1969).
   PubMed Web of Science ®Google Scholar
• Jodar L, Cartwright K, Feavers IM. Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines. Biologicals28, 193–197 (2000).
   PubMedGoogle Scholar
• Ram S. Binding of fH to meningococci is specific for human fH. Presented at: 15th International Pathogenic Neisseria Conference. Cairns, Queensland, Australia, 10–15 September 2006.
   Google Scholar
• Mandrell RE, Azmi FH, Granoff DM. Complement-mediated bactericidal activity of human antibodies to poly α 2→8 N-acetylneuraminic acid, the capsular polysaccharide of Neisseria meningitidis serogroup B. J. Infect. Dis.172, 1279–1289 (1995).
   PubMed Web of Science ®Google Scholar
• Zollinger WD, Mandrell RE. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect. Immun.40, 257–264 (1983).
   PubMed Web of Science ®Google Scholar
• Santos GF, Deck RR, Donnelly J et al. Importance of complement source in measuring meningococcal bactericidal titers. Clin. Diagn. Lab. Immunol.8, 616–623 (2001).
   PubMedGoogle Scholar
• Jodar L, Cartwright K, Feavers IM. Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines. Biologicals28, 193–197 (2000).
   PubMedGoogle Scholar
• Santos GF, Deck RR, Donnelly J, Blackwelder W, Granoff DM. Importance of complement source in measuring meningococcal bactericidal titers. Clin. Diagn. Lab. Immunol.8, 616–623 (2001).
   PubMedGoogle Scholar
• Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect. Immun.69, 1568–1573 (2001).
   PubMed Web of Science ®Google Scholar
• Donnelly J, Medini D, Boccadifuoco G et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc. Natl Acad. Sci. USA107(45), 19490–19495 (2010).
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Biolchi A, Serruto D et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine28(31), 5023–5030 (2010).
   PubMed Web of Science ®Google Scholar
• Wyle FA, Artenstein MS, Brandt BL et al. Immunological response of man to group B meningococcal polysaccharide antigens. J. Infect. Dis.126, 514–521 (1972).
   PubMed Web of Science ®Google Scholar
• Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis. Lancet2, 355–357 (1983).
   PubMed Web of Science ®Google Scholar
• Granoff DM. Review of meningococcal group B vaccines. Clin. Infect. Dis.50(2), S54–S65 (2010).
   PubMed Web of Science ®Google Scholar
• Holst J, Martin D, Arnold R et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine27(2), B3–B12 (2009).
   PubMed Web of Science ®Google Scholar
• Fredriksen JH, Rosenqvist E, Wedege E et al. Production, characterization and control of MenB-vaccine ‘Folkehelsa’: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann.14(2), 67–79, discussion 79–80 (1991).
   PubMedGoogle Scholar
• Vipond C, Suker J, Jones C, Tang C, Feavers IM, Wheeler JX. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254. Proteomics6, 3400–3413 (2006).
   PubMed Web of Science ®Google Scholar
• Williams JN, Skipp PJ, Humphries HE, Christodoulides M, O’Connor CD, Heckels JE. Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant. Infect. Immun.75, 1364–1372 (2007).
   PubMed Web of Science ®Google Scholar
• Bjune G, Høiby EA, Grønnesby JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet338, 1093–1096 (1991).
   PubMed Web of Science ®Google Scholar
• Sierra GV, Campa HC, Varcacel NM et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH14, 195–207 (1991).
   PubMedGoogle Scholar
• de Moraes JC, Perkins BA, Camargo MC et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet340, 1074–1078 (1992).
   PubMed Web of Science ®Google Scholar
• Caron F, du Chatelet IP, Leroy JP et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect. Dis.11(6), 455–463 (2011).
   PubMed Web of Science ®Google Scholar
• Boslego J, Garcia J, Cruz C et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine13, 821–829 (1995).
   PubMed Web of Science ®Google Scholar
• Tappero JW, Lagos R, Ballesteros AM, Plikaytis B et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA281(16), 1520–1527 (1999).
   PubMed Web of Science ®Google Scholar
• Rosenqvist E, Høiby EA, Wedege E et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun.63, 4642–4652 (1995).
   PubMed Web of Science ®Google Scholar
• Wedege E, Kuipers B, Bolstad K et al. Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine. Infect. Immun.71(7), 3775–3781 (2003).
   PubMed Web of Science ®Google Scholar
• Milagres LG, Gorla MC, Sacchi CT, Rodrigues MM. Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine. Infect. Immun.66(10), 4755–4761 (1998).
   PubMed Web of Science ®Google Scholar
• Milagres LG, Gorla MC, Rebelo MC, Barroso DE. Bactericidal antibody response to Neisseria meningitidis serogroup B in patients with bacterial meningitis: effect of immunization with an outer membrane protein vaccine. FEMS Immunol. Med. Microbiol.28(4), 319–327 (2000).
   PubMedGoogle Scholar
• Tappero JW, Lagos R, Ballesteros AM et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA281(16), 1520–1527 (1999).
   PubMed Web of Science ®Google Scholar
• Wedege E, Høiby EA, Rosenqvist E, Bjune G. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect. Immun.66(7), 3223–3231 (1998).
   PubMed Web of Science ®Google Scholar
• Rodriguez AP, Dickinson F, Baly A, Martinez R. The epidemiological impact of antimeningococcal B vaccination in Cuba. Mem. Inst. Oswaldo. Cruz.94, 433–440 (1999).
   PubMed Web of Science ®Google Scholar
• Oster P, Lennon D, O’Hallahan J, Mulholland K, Reid S, Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine23(17–18), 2191–2196 (2005).
   PubMed Web of Science ®Google Scholar
• Martin DR, Walker SJ, Baker MG, Lennon DR. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J. Infect. Dis.177(2), 497–500 (1998).
   PubMed Web of Science ®Google Scholar
• Devoy AF, Dyet KH, Martin DR. Stability of PorA during a meningococcal disease epidemic. J. Clin. Microbiol.43(2), 832–837 (2005).
   PubMed Web of Science ®Google Scholar
• Jódar L, Feavers IM, Salisbury D, Granoff DM. Development of vaccines against meningococcal disease. Lancet359(9316), 499–508 (2002).
   PubMed Web of Science ®Google Scholar
• Holst J, Feiring B, Fuglesang JE et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine21(7–8), 734–737 (2003).
   PubMed Web of Science ®Google Scholar
• Kelly C, Arnold R, Galloway Y, O’Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am. J. Epidemiol.166, 817–823 (2007).
   PubMed Web of Science ®Google Scholar
• Galloway Y, Stehr-Green P, McNicholas A, O’Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int. J. Epidemiol.38, 413–418 (2009).
   PubMed Web of Science ®Google Scholar
• Gorringe AR, Taylor S, Brookes C et al. Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Clin. Vaccine Immunol.16, 1113–1120 (2009).
   PubMedGoogle Scholar
• Bennett JS, Griffiths DT, McCarthy ND et al. Genetic diversity and carriage dynamics of Neisseria lactamica in infants. Infect. Immun.73, 2424–2432 (2005).
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay TK, Halliwell D, O’Dwyer C et al. Rapid characterisation of outer membrane proteins in Neisseria lactamica by surface enhanced laser desorption and ionisation – time of flight mass spectroscopy for use in a meningococcal vaccine. Biotechnol. Appl. Biochem.41, 175–182 (2005).
   PubMed Web of Science ®Google Scholar
• Oliver KJ, Reddin KM, Bracegirdle P et al.Neisseria lactamica protects against experimental meningococcal infection. Infect. Immun.70, 3621–3626 (2002).
   PubMed Web of Science ®Google Scholar
• Keiser PB, Biggs-Cicatelli S, Moran EE et al. A Phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine29, 1413–1420 (2011).
   PubMed Web of Science ®Google Scholar
• Zollinger WD, Donets MA, Schmiel DH et al. Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine28(31), 5057–5067 (2010).
   PubMed Web of Science ®Google Scholar
• Tondella ML, Popovic T, Rosenstein NE et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The active bacterial core surveillance team. J. Clin. Microbiol.38, 3323–3328 (2000).
   PubMed Web of Science ®Google Scholar
• Holst J. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them. Hum. Vaccine3, 290–294 (2007).
   PubMed Web of Science ®Google Scholar
• Holst J, Feiring B, Naess LM et al. The concept of ‘tailor-made,’ protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine23, 2202–2205 (2005).
   PubMed Web of Science ®Google Scholar
• Sandbu S, Feiring B, Oster P et al. Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines. Clin. Vaccine Immunol.14, 1062–1069 (2007).
   PubMed Web of Science ®Google Scholar
• Boutriau D, Poolman J, Borrow R et al. Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7–2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin. Vaccine Immunol.14(1), 65–73 (2007).
   PubMed Web of Science ®Google Scholar
• Claassen I, Meylis J, van der Ley P et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine14, 1001–1008 (1996).
   PubMed Web of Science ®Google Scholar
• van der Ley P, vander Biezen J, Poolman JT. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine13, 401–407 (1995).
   PubMed Web of Science ®Google Scholar
• Rots NY, Kleijne DE. Safety of a nonavalent meningococcal serogroup B vaccine in healthy adult volunteers in a randomised, controlled, single blind study. Presented at: 16th International Pathogenic Neisseria Conference. Rotterdam, The Netherlands, 7–12 September 2008.
   Google Scholar
• de Kleijn ED, de Groot R, Labadie J et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2–3 and 7–8 years of age. Vaccine18, 1456–1466 (2000).
   PubMed Web of Science ®Google Scholar
• Cartwright K, Morris R, Rumke H et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine17, 2612–2619 (1999).
   PubMed Web of Science ®Google Scholar
• Peeters CC, Rumke HC, Sundermann LC et al. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine14, 1009–1015 (1996).
   PubMed Web of Science ®Google Scholar
• Van der Ley P, Poolman JT. Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein. Infect. Immun.60, 3156–3161 (1992).
   PubMed Web of Science ®Google Scholar
• Rouppe van der Voort E, Schuller M, Holst J et al. Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys. Vaccine18, 1334–1343 (2000).
   PubMed Web of Science ®Google Scholar
• van den Dobbelsteen GP, van Dijken HH, Pillai S, van Alphen L. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine25, 2491–2496 (2007).
   PubMed Web of Science ®Google Scholar
• Russell JE, Jolley KA, Feavers IM, Maiden MC, Suker J. PorA variable regions of Neisseria meningitidis. Emerg. Infect. Dis.10, 674–678 (2004).
   PubMed Web of Science ®Google Scholar
• Sacchi CT, Whitney AM, Popovic T et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992–1998. J. Infect. Dis.182, 1169–1176 (2000).
   PubMed Web of Science ®Google Scholar
• Lennon D, Jackson C, Wong S, Horsfall M, Stewart J, Reid S. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clin. Infect. Dis.49(4), 597–605 (2009).
   PubMed Web of Science ®Google Scholar
• Harrison LH, Jolley KA, Shutt KA et al. Antigenic shift and increased incidence of meningococcal disease. J. Infect. Dis.193, 1266–1274 (2006).
   PubMed Web of Science ®Google Scholar
• Tettelin H, Saunders NJ, Heidelberg J et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science287, 1809–1815 (2000).
   PubMed Web of Science ®Google Scholar
• Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine19(17–19), 2688–2691 (2001).
   PubMed Web of Science ®Google Scholar
• Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity33(4), 530–541 (2010).
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Adu-Bobie J, Comanducci M et al. A universal vaccine for serogroup B meningococcus. Proc. Natl Acad. Sci. USA103(29), 10834–10839 (2006).
   PubMed Web of Science ®Google Scholar
• Comanducci M, Bambini S, Brunelli B et al. NadA, a novel vaccine candidate of Neisseria meningitides. J. Exp. Med.195(11), 1445–1454 (2002).
   PubMed Web of Science ®Google Scholar
• Serruto D, Spadafina T, Ciucchi L et al.Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc. Natl Acad. Sci. USA107(8), 3770–3775 (2010).
   PubMed Web of Science ®Google Scholar
• Miller E, Pollard AJ, Borrow R et al. Safety and immunogenicity of Novartis meningococcal serogroup B vaccine after three doses administered in infancy. Presented at: 26th Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID), Graz, Austria, 13–17 May 2008.
   Google Scholar
• Snape M, Dawson T, Oster P et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr. Infect. Dis. J.29(11), 71–79 (2010).
   PubMed Web of Science ®Google Scholar
• Vesikari T et al. Immunogenicity of an investigational multicomponent meningococcal serogroup B vaccine in healthy infants at 2, 4 and 6 months of age. Presented at: 17th International Pathogenic Neisseria Conference. Banff, Canada, 11–16 September 2010.
   Google Scholar
• Esposito S et al. Tolerability of a three-dose schedule of investigational, multicomponent meningococcal serogroup B vaccine and routine infant vaccines in a lot consistency trial. Presented at: 17th International Pathogenic Neisseria Conference. Banff, Canada, 11–16 September 2010.
   Google Scholar
• Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroup A, C, W-135 and Y in adult who are at increased risk for occupational exposure to meningococcal isolated. Clin. Vaccine Immunol.18(3), 483–486 (2011).
   PubMed Web of Science ®Google Scholar
• Brehony C, Wilson DJ, Maiden MC. Variation of the factor H-binding protein of Neisseria meningitidis. Microbiology155(12), 4155–4169 (2009).
   PubMed Web of Science ®Google Scholar
• Murphy E, Andrew L, Lee KL et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J. Infect. Dis.200(3), 379–389 (2009).
   PubMed Web of Science ®Google Scholar
• Perrett KP, Pollard AJ. Towards and improved serogroup B Neisseria meningitides vaccine. Expert Opin. Biol. Ther.5, 1611–1625 (2005).
   PubMed Web of Science ®Google Scholar
• Lucidarme J, Comanducci M, Findlow J et al. Characterization of fHbp, NHBA (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J. Clin. Microbiol.47(11), 3577–3585 (2009).
   PubMed Web of Science ®Google Scholar
• Fletcher LD, Bernfield L, Barniak V et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun.72, 2088–2100 (2004).
   PubMed Web of Science ®Google Scholar
• Fletcher L, Farley J, Bernfield L et al. Characterization, cloning and expression of different subfamilies of the ORF 2086 gene from Neisseria meningitidis, Presented at: 13th International Pathogenic Neisseria Conference. National Institute of Public Health, Oslo, Norway, 1–6 September 2002.
   Google Scholar
• Zhu D, Zhang Y, Barniak V, Bernfield L, Howell A, Zlotnick G. Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model. Infect. Immun.73(10), 6838–6845 (2005).
   PubMed Web of Science ®Google Scholar
• Nissen MD, Marshall KS, Richmond P et al. A randomized, placebo-controlled, double-blind, Phase I trial of ascending dose of meningococcal group B rLP2086 vaccine. Presented at: 26th Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID). Graz, Austria, 13–17 May 2008.
   Google Scholar
• Richmond P, Marshall H, Sheldon E et al. Safety and immunogenicity of serogroup B Neisseria meningitidis (MnB) rLP2086 vaccine in adults and adolescent subjects: overview of 3 clinical trials. Presented at: 17th International Pathogenic Neisseria Conference. Banff, Albert, Canada, 11–16 September 2010.
   Google Scholar
• Maiden MC, Ibarz-Pavon AB, Urwin R et al. Impact of meningococcal serogroup C coniugate vaccines on carriage and herd immunity. J. Infect. Dis.197, 737–743 (2008).
   PubMed Web of Science ®Google Scholar
• O’Hallahan J, Lennon D, Oster P et al. From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal diasease. Vaccine23, 2197–2201 (2005).
   PubMed Web of Science ®Google Scholar
• Beernink PT, Welsch JA, Harrison LH, Leipus A, Kaplan SL, Granoff DM. Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J. Infect. Dis.195(10), 1472–1479 (2007).
   PubMed Web of Science ®Google Scholar
• Masignani V, Comanducci M, Giuliani MM et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med.197, 789–799 (2003).
   PubMed Web of Science ®Google Scholar
• Beernink PT, Granoff DM. Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines. Infect. Immun.76(6), 2568–2575 (2008).
   PubMed Web of Science ®Google Scholar
• Welsch JA, Rossi R, Comanducci M, Granoff DM. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J. Immunol.172(9), 5606–5615 (2004).
   PubMed Web of Science ®Google Scholar
• Welsch JA, Ram S, Koeberling O, Granoff DM. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J. Infect. Dis.197, 1053–1061 (2008).
   PubMed Web of Science ®Google Scholar
• Seib KL, Serruto D, Oriente F et al. Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect. Immun.77, 292–299 (2009).
   PubMed Web of Science ®Google Scholar
• Harrison LH, Pelton SI, Wilder-Smith A et al. The global meningococcal initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine29, 3363–3371 (2011).
   PubMedGoogle Scholar
• Findlow J, Lucidarme J, Comanducci M et al. Characterisation of fhbp, nhba, nadA, porA and sequence type in meningococcal group B case isolates collected in England and Wales in the epidemiological year 2007/2008, and the potential coverage of an investigational group B vaccine. Presented at: 17th International Pathogenic Neisseria Conference. Banff, Canada, 11–16 September 2010.
   Google Scholar
• Cohn AC, Wang X, MacNeil JR et al. Potential impact of serogroup B vaccines: prevalence of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Presented at: IPNC 2010, 17th International Pathogenic Neisseria Conference. Banff, Canada, 11–16 September 2010.
   Google Scholar
• Holst J, Bambini S, Muzzi A et al. Sequence variation and degree of expression for five genome-derived vaccine antigens included in the MenB Novartis investigational vaccine. Presented at: IPNC 2010, 17th International Pathogenic Neisseria Conference. Banff, Canada, 11–16 September 2010.
   Google Scholar
• Muzzi A, Bambini S, Comandi S et al. Factor H binding protein (fHbp) variability within the ST-41 and ST-44 sub-complexes of cc41/44. Presented at: IPNC 2010, 17th International Pathogenic Neisseria Conference. Banff, Canada, 11–16 September 2010.
   Google Scholar
• Findlow J, Borrow R, Snape MD et al. Multicenter, open-label, randomized Phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis.51(10), 1127–1137 (2010).
   PubMed Web of Science ®Google Scholar
• Taha MK, Alonso JM. Meningococcal vaccines: to eradicate the disease, not the bacterium. Hum. Vaccines3(4), 149–152 (2007).
   PubMed Web of Science ®Google Scholar
• Horton RE, Stuart J, Christensen H et al. Influence of age and carriage status on salivary IgA to Neisseria meningitidis. Epidemiol. Infect.133, 883–889 (2005).
   PubMed Web of Science ®Google Scholar
• Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect. Dis.10, 853–861 (2010).
   PubMed Web of Science ®Google Scholar
• Davenport V, Groves E, Horton RE et al. Mucosal immunity in healthy adults after parenteral vaccination with outer-membrane vesicles from Neisseria meningitidis serogroup B. J. Infect. Dis.198, 731–740 (2008).
   PubMed Web of Science ®Google Scholar